Stockreport

Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update

Compass Therapeutics, Inc.  (CMPX) 
PDF Enrollment in COMPANION-002, the Phase 2/3 randomized study of CTX-009 (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC), continue [Read more]